Activated partial thromboplastin time (APTT) is commonly used to control treatment with unfractionated (standard) heparin in dogs 6, 8 and in humans. 3, 12 Originally, it has been recommended that the therapeutic range in humans should be a 1.5-to 2.5-fold From the Clinic for Small Animals, School of Veterinary Medicine Hannover, Bischofsholer Damm 15, D-30173 Hannover, Germany. prolongation of baseline values. 2 This has become generally accepted as an indicator of an adequate heparin plasma activity for treatment of venous thromboembolism. 1, 12, 14, 20 However, different investigations in humans demonstrated remarkable differences in APTT reagents regarding their heparin sensitivity. 7, 9, 13, 16, 19 In dogs, the recommendations for the aspired APTT prolongation in human thrombosis therapy (1.5-to 2.5times baseline) have been used without validation, 6, 8 Figure 1 . Activated partial thromboplastin time ratio (mean Ϯ SD, n ϭ 6) (APTT ratio ϭ actual APTT/mean APTT control) at different heparin activities measured after in vitro addition of heparin to normal canine plasma (reagent 1 ϭ Pathromtin, 2 ϭ PTT Reagent, 3 ϭ APTT Reagent, 4 ϭ APTT-FS Reagent, 5 ϭ Actin FS, 6 ϭ Dapttin, see Table 1 ).
although coagulation factor activities in dogs differ considerably from those in humans. 10 The aim of the present study was to define the heparin sensitivity of different commercial APTT reagents in canine plasma based on samples with defined heparin activities.
The in vitro heparin sensitivity of different APTT reagents was investigated using artificial plasma samples prepared by adding sodium heparin to pooled normal canine plasma. The following final heparin activities were used: 0 (without heparin, control), 0.05, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2, and 1.5 IU/ ml. To eliminate influences dependent on heparin preparation and canine plasma, each heparin activity level was prepared using 3 different commercial sodium heparin solutions a-c added to 1 of the 3 pooled canine plasma samples. Each combination was measured in duplicate, i.e., 6 measurements were taken at each heparin activity level. As a measure of sensitivity, APTT ratios were calculated by dividing the actual APTT by the mean APTT control.
Blood samples were obtained from the cephalic or saphenous vein of clinically healthy dogs. The dogs were of different sex and breed and had fasted for at least 12 hours. They had normal complete blood cell counts and clinical chemistry profiles. Blood was collected into tubes containing 0.11 mol/liter sodium citrate solution d (9 parts blood and 1 part citrate solution). To obtain platelet-poor plasma (PPP), blood samples were centrifuged at 2,000 ϫ g for 20 minutes at 4 C. Plasma samples were stored in small aliquots (Ͻ500 l) at Ϫ70 C and were thawed at 37 C immediately before measurements were made. Three different pooled plasma preparations were made by mixing aliquots of Ն 20 healthy dogs each. The original heparin solutions containing 5,000 IU heparin/ml were diluted stepwise with pooled plasma to result in canine plasma samples with the heparin activities cited above.
The APTT was measured using a semiautomatic crochet coagulometer. e The following 6 commercial APTT reagents were used in the study: Pathromtin (kaolin [activator] and human placenta [phospholipid], reagent 1), PTT Reagent (kaolin and rabbit brain, reagent 2), APTT Reagent (ellagic acid and rabbit brain, reagent 3), APTT-FS Reagent (ellagic acid and soybean phospholipid, reagent 4), Actin FS (ellagic acid and soybean phospholipid, reagent 5), and Dapttin (kaolin and sulfatide [activator], origin of phospholipid not given by the manufacturer, reagent 6) ( Table 1) . Only 1 defined batch of each reagent was used in the study.
The APTT reagents 1, 2, and 6 were reconstituted according to the manufacturers' test instructions. The lyophilized reagent 6 was dissolved in 2 ml of distilled water. The lyophilized phospholipid preparation of reagents 1 and 2 was dissolved in 2 ml kaolin solution. The other reagents were supplied ready for use.
Considering the special features of the individual reagents given by the manufacturers (Table 1) , the APTT was determined according to the following test instruction: 100 l PPP (for some reagents prewarmed for 1 minute at 37 C), 100 l APTT reagent (for some reagents prewarmed to 37 C), incubation for 2 or 3 minutes at 37 C, addition of 100 l CaCl 2 solution (37 C; 20 f or 25 g mmol/liter), and simultaneous start of the stop watch. The time until formation of the first fibrin strand was measured by the coagulometer.
Arithmetic mean values and SD were used as descriptive parameters. Two-way analysis of variance was used to compare the APTT ratios obtained using different APTT reagents at different heparin activities. Results of individual reagents were compared using the Scheffé test. Significance was set at P Ͻ 0.05.
Two-way analysis of variance revealed significant differences between the APTT ratios of different APTT reagents (P Ͻ 0.00001), which also depended on the heparin activity (interaction between the factors; P Ͻ 0.00001). For example, mean APTT ratios at 0.3 IU/ml heparin varied between 1.1 (reagent 6) and 1.4 (reagent 1), and APTT ratios at 0.7 IU/ml heparin varied between 1.2 and 2.5 (Fig. 1 ). On the contrary, an APTT ratio of 1.5 was associated with heparin activity levels between 0.3 (reagent 1) and 1.2 IU/ml (reagent 6), and an APTT ratio of 2.5 was associated with heparin activity levels between 0.7 (reagent 1) and Ͼ1.5 IU/ml. No statistically significant difference (Scheffé test) was found between reagents 1 and 2 (P ϭ 0.0532), 2 and 4 (P ϭ 0.4629), and 5 and 6 (P ϭ 0.0939), whereas the APTT ratio between all other reagents differed significantly (P Ͻ 0.0001). Generally, the reagents containing kaolin as the sole contact activator (reagents 1 and 2) had a higher heparin sensitivity than reagents based on ellagic acid (reagents 3-5). The lowest heparin sensitivity was observed for reagent 6 (Dapttin). The results of the present investigation demonstrated that the APTT ratio of a canine plasma sample with a defined heparin activity depends remarkably on the reagent used. This confirmed the results of similar studies on ex vivo-or in vitro-prepared human samples. 4, 7, 9, 12, 13, 16, [18] [19] [20] These differences reflect variations in the chemical composition (e.g., phospholipid type, contact activator) and activation time. 9 The results of the present study may indicate a generally higher heparin sensitivity of APTT reagents containing kaolin as a contact activator when compared with ellagic acidbased reagents, which is in agreement with the results of a study in humans comparing 2 APTT reagents. 20 However, this was not confirmed by other studies on human samples based on a greater number of APTT reagents. 7, 16 Reagent 6, which contained a mixture of kaolin and sulfatide as the contact activator and for which the lowest heparin sensitivity was demonstrated in the present study, also showed a very low heparin sensitivity in similar studies performed on human samples. 7 Apart from reagent-related differences, the use of a fixed APTT ratio range as the guideline to monitor heparin therapy must also be critically appraised because differences in APTT ratios may also be due to the method used. 4, 5, 7, 9, 13, 19 For example, mechanical principles are associated with lower APTT ratios compared with measurements based on photooptical devices. 7 In addition, lot-to-lot variation in heparin sensitivity was reported for 1 brand of APTT reagent. 15, 17 Thus, it also became clear in humans that, in many laboratories, an APTT result that was 1.5-to 2.5-times the control is not equivalent to therapeutic heparin activities. 9, 12, 14, 16 Consequently, it is recommended for humans that each laboratory should establish an individual therapeutic APTT ratio range for the heparin preparation used and for its own reagent and instrument system. 3, 9, 17 The APTT reagent and equipment used to measure APTT should be calibrated with heparin activities equivalent to the limits of the therapeutic range for thrombosis treatment in humans (0.3-0.7 IU/ml as determined by an antifactor Xa assay). 3, 14 The results of the present study indicate that although APTT standardization will not be simple, it is much needed for dogs as well. No recommendations are available for dogs regarding effective heparin activities in canine plasma. Because the coagulation factor II and X activities that are the most important for the anticoagulatory effect of heparin are approximately equivalent in human and canine plasma, 10 the dosage regimen of heparin therapy for dogs should probably be orientated to the recommendations for amidolyticdetermined plasma heparin activities in humans.
To standardize heparin sensitivity in humans, frequently, normal plasma samples with in vitro addition of heparin have been used as was the case in the present investigation (in vitro sensitivity). 3, 4, 7, 16, 19 If available, however, ex vivo specimens from heparinized patients with known amidolytic heparin activities should be preferably used because the in vivo situation may differ from the situation with artificial samples prepared in vitro. [3] [4] [5] 12, 13, 18, 19 Commercial heparin calibrators that are now available for human plasma cannot be used to standardize heparin sensitivity in canine plasma. Comparison of the data of the this study with those found in analogous studies for human samples 16, 19 demonstrates that for a given heparin plasma activity, APTT is less prolonged in dogs than in humans.
A further concept to standardize APTT in humans is the attempt to calibrate heparin sensitivity of reagents against a commercial reference APTT reagent, using the International sensitivity Index (ISI)/International normalized ratio (INR) system that has worked well for the calibration of the prothrombin time for oral anticoagulant therapy control. 13, 19 However, once given, HISI values (following the calculation of regent-independent INR) cannot be extrapolated to dogs because of species differences.
When using the APTT for heparin control, the moderate correlation between APTT ratio and heparin activities measured by chromogenic substrates has to be additionally considered in dogs 11 and in humans. 1, 9, 14, 18 Heparin therapy monitored by amidolytic heparin activity levels may be more effective and safer. 1, 14 The significant heparin sensitivity differences between different APTT reagents indicate that recommendations for the control of heparin therapy by APTT should be reagent specific.
Sources and manufacturers
a. Liquemin (lot no. 30911), Hoffmann-La-Roche AG, Basel, Switzerland. b. Heparin-Natrium 25.000 medac (lot no. 53101), medac, Gesellschaft für klinische Spezialpräparate mbH, Wedel, Germany. c. Heparin-Natrium-25.000-ratiopharm, ratiopharm GmbH, Ulm, Germany. d. Sodium citrate, Roche Diagnostics GmbH, Mannheim, Germany. e. Coagulometer according to Schnitger and Gross, Heinrich Amelung GmbH, Lemgo, Germany. f. Calcium Chloride Solution 0.02 mol/liter, Sigma Diagnostics, St.
Louis, MO. g. CaCl 2 0.025 M, Diagnostica Stago, Roche Diagnostics GmbH, Mannheim, Germany.
